attention deficit hyperactivity disorder

Akili adds to ADHD gaming range with £37m TALi licensing deal

Akili already has the first and only FDA cleared video game-based digital therapeutic (DTx) for children with attention-deficit hyperactivity disorder (ADHD), but is looking to add to its range via a licensing deal with Australia’s TALi Digital.  Flush with cash from a recent $160 million equity and debt financing, Akili has agreed to license US …

Akili adds to ADHD gaming range with £37m TALi licensing deal Read More »

Supernus ADHD drug is FDA approved; first new ‘non-stimulant’ med in a decade

FDA approval of Supernus Pharmaceuticals drug Qelbree gives attention-deficit hyperactivity disorder patients another treatment option that is not classified as a Schedule II substance. It’s a different formulation of a drug that was first approved in Europe decades ago.